BLFS (BioLife Solutions) 3-Year EBITDA Growth Rate: 0.00% (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BLFS BioLife Solutions Inc BLFS
72 GF Score
Price $29.11
GF Value $28.89
Valuation Fairly Valued
! 5 Warning Signs
View Full Analysis

What is BioLife Solutions 3-Year EBITDA Growth Rate?

BioLife Solutions BLFS -3.70% 72 3-Year EBITDA Growth Rate is 0.00% as of Mar. 2026. GuruFocus rates BLFS with a GF Score™ of 72/100 and a GF Value™ of $28.89 (Fairly Valued). The stock has 5 warning signs investors should review. Among 692 Medical Devices & Instruments companies, BioLife Solutions ranks worse than 144508.53% on this metric.

BioLife Solutions's EBITDA per Share for the three months ended in Mar. 2026 was $0.02.

During the past 12 months, BioLife Solutions's average EBITDA Per Share Growth Rate was -285.40% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of BioLife Solutions was 58.50% per year. The lowest was -215.90% per year. And the median was 7.20% per year.

BioLife Solutions  (NAS:BLFS) 3-Year EBITDA Growth Rate Explanation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

BioLife Solutions 3-Year EBITDA Growth Rate Related Terms

BLFS vs STAA, ATRC, KMTS: 3-Year EBITDA Growth Rate Comparison

For the Medical Instruments & Supplies subindustry, BioLife Solutions's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

BioLife Solutions 3-Year EBITDA Growth Rate vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, BioLife Solutions's 3-Year EBITDA Growth Rate distribution charts can be found below:

* The bar in red indicates where BioLife Solutions's 3-Year EBITDA Growth Rate falls into.


BLFS
72GF Score
BioLife Solutions Inc BLFS
3-Year EBITDA Growth Rate is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

BioLife Solutions 3-Year EBITDA Growth Rate Calculation

This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

What does a 3-Year EBITDA Growth Rate of 0.00% mean?
BioLife Solutions (BLFS) has a 3-Year EBITDA Growth Rate of 0.00% as of Mar. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for BioLife Solutions and its competitors. According to the industry distribution chart, BioLife Solutions ranks #999999 out of 692 companies in the Medical Devices & Instruments industry.
Is BioLife Solutions' 3-Year EBITDA Growth Rate too high?
BioLife Solutions' current 3-Year EBITDA Growth Rate is 0.00%. Based on the distribution chart, BioLife Solutions ranks #999999 out of 692 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, BioLife Solutions has a GF Score™ of 72/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does BioLife Solutions' 3-Year EBITDA Growth Rate compare to STAA and ATRC?
According to the Medical Devices & Instruments industry distribution chart, BioLife Solutions ranks #999999 out of 692 companies for 3-Year EBITDA Growth Rate. This places BioLife Solutions in the lower half of its industry. The industry median 3-Year EBITDA Growth Rate is 7.65. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Medical Devices & Instruments company?
The median 3-Year EBITDA Growth Rate among Medical Devices & Instruments companies is 7.65, based on 692 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for BioLife Solutions and its competitors. For the Medical Devices & Instruments industry, the median 3-Year EBITDA Growth Rate is 7.65 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. BioLife Solutions's current 3-Year EBITDA Growth Rate is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioLife Solutions stock overvalued right now?
Based on GuruFocus' analysis, BioLife Solutions (BLFS) is currently considered Fairly Valued. The stock's GF Value™ is $28.89, compared to a current price of $29.11 — trading 0.8% above its estimated fair value. The current 3-Year EBITDA Growth Rate is 0.00%. BioLife Solutions' overall GF Score™ is 72/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For BioLife Solutions (BLFS), the current 3-Year EBITDA Growth Rate is 0.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is BioLife Solutions (BLFS) Overvalued in 2026?

Based on GuruFocus' analysis, BioLife Solutions stock appears to be overvalued. The current stock price of $29.11 is trading 0.8% above its estimated GF Value™ of $28.89. GuruFocus considers BioLife Solutions to be Fairly Valued.

Key valuation signals for BLFS:

  • 3-Year EBITDA Growth Rate: 0.00%
  • GF Value™: $28.89 vs. price of $29.11 (0.8% above fair value)
  • GF Score™: 72/100 with 5 warning signs

No single metric tells the full story. See the BLFS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

BioLife Solutions Business Description

Other Exchanges BJX1:Germany
Address 3303 Monte Villa Parkway, Suite 310, Bothell, WA, USA, 98021
BioLife Solutions Inc is a life sciences company that develops, manufactures, and markets bioproduction products and services that are designed to improve quality and de-risk biologic manufacturing, distribution, and transportation in the cell and gene therapy ("CGT") industry. The company provides solutions such as Cell Processing, Cold Chain, and Thawing. The company generates the majority of its revenue from Cell Processing through the biopreservation product "CryoStor". Geographically the company generates the majority of its revenue from the United States.
72GF Score

Get the complete analysis for BLFS

3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$29.11
Price
$28.89
GF Value